The estimated Net Worth of William Mariner Greenman is at least $10.1 million dollars as of 12 March 2024. Mr. Greenman owns over 125,926 units of Cerus stock worth over $6,521,626 and over the last 18 years he sold CERS stock worth over $348,839. In addition, he makes $3,270,180 as President, Chief Executive Officer et Director at Cerus.
William has made over 26 trades of the Cerus stock since 2011, according to the Form 4 filled with the SEC. Most recently he sold 125,926 units of CERS stock worth $256,889 on 12 March 2024.
The largest trade he's ever made was exercising 550,000 units of Cerus stock on 16 April 2021 worth over $1,485,000. On average, William trades about 45,403 units every 76 days since 2006. As of 12 March 2024 he still owns at least 3,181,281 units of Cerus stock.
You can see the complete history of Mr. Greenman stock trades at the bottom of the page.
William M. Greenman serves as President, Chief Executive Officer, Director of the Company. Mr. Greenman served as our Senior Vice President, Business Development and Marketing from August 2008 until April 2011 and was named our Chief Business Officer in April 2010. Mr. Greenman served as our President, Cerus Europe, from 2006 until August 2008. From 1999 to 2006, Mr. Greenman served as our Vice President, Business Development after returning to Cerus after a brief time in the venture capital business. Prior to joining us in 1995 as Director of Business Development, Mr. Greenman worked in various marketing and business development positions in Baxter’s Biotech Division from 1991 to 1995. Mr. Greenman has served on the board of directors of Aduro Biotech, Inc., a public clinical-stage immunotherapy company, since June 2010. Mr. Greenman holds a B.A.S. in economics and biological sciences from Stanford University.
As the President, Chief Executive Officer et Director of Cerus, the total compensation of William Greenman at Cerus is $3,270,180. There are no executives at Cerus getting paid more.
William Greenman is 53, he's been the President, Chief Executive Officer et Director of Cerus since 2011. There are 10 older and 3 younger executives at Cerus. The oldest executive at Cerus Corp. is Laurence Corash, 76, who is the Chief Scientific Officer.
William's mailing address filed with the SEC is C/O CERUS CORPORATION, 1220 CONCORD AVE SUITE 600, CONCORD, CA, 94520.
Over the last 21 years, insiders at Cerus have traded over $5,083,598 worth of Cerus stock and bought 1,382,745 units worth $4,903,526 . The most active insiders traders include William Mariner Greenman, Laurence M Corash et Bruce C Cozadd. On average, Cerus executives and independent directors trade stock every 33 days with the average trade being worth of $90,805. The most recent stock trade was executed by Kevin Dennis Green on 3 September 2024, trading 82,657 units of CERS stock currently worth $178,539.
cerus corporation is a biomedical products company focused on commercializing the intercept blood system to enhance blood safety. the intercept system is designed to reduce the risk of transfusion-transmitted diseases by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. the nucleic acid targeting mechanism of action enables intercept treatment to inactivate established transfusion threats, such as hepatitis b and c, hiv, west nile virus and bacteria, and is designed to inactivate emerging pathogens such as influenza, malaria and dengue. cerus currently markets and sells the intercept blood system for both platelets and plasma in europe, russia, the middle east and selected countries in other regions around the world. the intercept red blood cell system is in clinical development.
Cerus executives and other stock owners filed with the SEC include: